Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients

被引:15
作者
Chien, JW
Valdez, H
McComsey, G
McClernon, D
St Clair, M
Lederman, MM
机构
[1] Univ Hosp Cleveland, Div Infect Dis, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, AIDS Res Ctr, Cleveland, OH 44106 USA
[3] Glaxo Wellcome Inc, Dept Virol, Res Triangle Pk, NC 27709 USA
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 1999年 / 21卷 / 04期
关键词
lamivudine; resistance; mutation; cerebrospinal fluid; antiretroviral agents;
D O I
10.1097/00126334-199908010-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To explore the relation between levels of HIV-1 in the cerebrospinal fluid (CSF) and plasma, simultaneously obtained samples from twelve patients who were receiving or had received lamivudine were examined; HIV-1 RNA levels were measured by nucleic acid sequence-based amplification procedure (NASBA). HIV-1 pol gene was amplified and sequenced. Median plasma and CSF HIV-1 RNA levels were 4.98 log and 2.93 log respectively. In total, 5 patients had CSF levels <100 copies/ml. A significant correlation between plasma and CSF HIV-1 RNA levels was found; 3 patients with disproportionately elevated CSF HIV-l RNA levels had clinical evidence of central nervous system disease. Genotypic analysis was available for 9 plasma/CSF pairs. In 4, the lamivudine (3TC)-resistance mutation M184V was found in both CSF and plasma. Discordance was found in 2 pairs. In both, M184V was found in plasma but not CSF. These data suggest that CSF and plasma levels of HIV-1 may be correlated.
引用
收藏
页码:277 / 280
页数:4
相关论文
共 12 条
[1]   RAPID AND SIMPLE METHOD FOR PURIFICATION OF NUCLEIC-ACIDS [J].
BOOM, R ;
SOL, CJA ;
SALIMANS, MMM ;
JANSEN, CL ;
WERTHEIMVANDILLEN, PME ;
VANDERNOORDAA, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (03) :495-503
[2]  
CAMERON DW, 1998, 5 C RETR OPP INF CHI
[3]  
CUNNINGHAM P, 1998, 5 C RETR OPP INF CHI
[4]  
DiStefano M, 1997, AIDS, V11, P698
[5]   Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine [J].
Foudraine, NA ;
Hoetelmans, RMW ;
Lange, JMA ;
de Wolf, F ;
van Benthem, BHB ;
Mass, JJ ;
Keet, IPM ;
Portegies, P .
LANCET, 1998, 351 (9115) :1547-1551
[6]  
GISOLF E, 1998, 5 C RETR OPP INF CHI
[7]   The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine [J].
Gisslen, M ;
Norkrans, G ;
Svennerholm, B ;
Hagberg, L .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (02) :434-437
[8]   Decline in deaths from AIDS due to new antiretrovirals [J].
Hogg, RS ;
OShaughnessy, MV ;
Gataric, N ;
Yip, B ;
Craib, K ;
Schechter, MT ;
Montaner, JSG .
LANCET, 1997, 349 (9061) :1294-1294
[9]   Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain [J].
McArthur, JC ;
McClernon, DR ;
Cronin, MF ;
NanceSproson, TE ;
Saah, AJ ;
StClair, M ;
Lanier, ER .
ANNALS OF NEUROLOGY, 1997, 42 (05) :689-698
[10]   Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres [J].
Mouton, Y ;
Alfandari, S ;
Valette, M ;
Cartier, F ;
Dellamonica, P ;
Humbert, G ;
Lang, JM ;
Massip, P ;
Mechali, D ;
Leclercq, P ;
Modai, J ;
Portier, H .
AIDS, 1997, 11 (12) :F101-F105